Archive for the ‘psoriatic arthritis’ Category

Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials

Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…

Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis

Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…

Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya approval in U.S. for psoriatic arthritis looks likely

Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…

Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis
Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis

AbbVie, the North Chicago company behind the longtime blockbuster biologic Humira (adalimumab) and the new biologic Skyrizi (risankizumab-rzaa), has asked the U.S. Food and Drug Administration (FDA) and its European counterpart to approve its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for psoriatic arthritis. Rinvoq is a JAK inhibitor administered as Continue Reading…

Our new “Psoriasis Journey” campaign is rolling out
Our new “Psoriasis Journey” campaign is rolling out

Our new Psoriasis Journey campaign is rolling out now to prep for for an official June 8, 2020 launch. On that date, our volunteer patient with severe psoriasis is going to begin one of the cutting-edge psoriasis treatments we’ve been hearing so much about. You can follow along with his Continue Reading…

Cosentyx goes head to head against Humira in psoriatic arthritis…it’s mostly a draw
Cosentyx goes head to head against Humira in psoriatic arthritis…it’s mostly a draw

Two biologics that work on psoriatic disease differently – Cosentyx (drug name secukinumab, an IL-17a inhibitor) and Humira (drug name adalimumab, a TNF-alpha inhibitor) – were recently tested in a study designed and funded by Novartis, the company behind Cosentyx. The study pitted Cosentyx against Humira for 52 weeks in Continue Reading…

New patient registry PsoProtect for those battling both psoriasis and COVID-19/coronavirus could help provide treatment insights to both ailments
New patient registry PsoProtect for those battling both psoriasis and COVID-19/coronavirus could help provide treatment insights to both ailments

Scientists and physicians in the UK, working with an international coalition of experts and organizations, have launched a web-based registry that will gather health information on people with psoriasis who develop confirmed or suspected COVID-19/coronavirus. The results, if enough doctors participate, could provide important information in the treatment of both Continue Reading…

Amgen to test Otezla as possible COVID-19 coronavirus treatment
Amgen to test Otezla as possible COVID-19 coronavirus treatment

Biotech giant Amgen, known in the psoriasis world for its longtime blockbuster Enbrel (etanercept), a biologic used in the treatment of psoriasis and psoriatic arthritis, has announced that the company “plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.” Continue Reading…

Opioid use “substantial” among people with moderate to severe psoriasis

A recent study looked at a database of privately insured people that included about 9,000 psoriasis patients, of whom just over 2,000 were identified as having moderate to severe psoriasis. It found that about 25% of those 2,000 received opioids, compared to 16% of otherwise-comparable people without psoriasis. The figure Continue Reading…

Big Mac please, hold the broccoli
Big Mac please, hold the broccoli

Today we report a study merely as a reminder that just because it is in a scientific journal does not make it the Gospel. It was a very small study, out of Japan, based on self-reported dietary history questionnaires. (The accuracy of self-reported dietary histories is probably right up there Continue Reading…